[go: up one dir, main page]

WO2001090401A2 - Souches de levure permettant d'identifier des inhibiteurs specifiques de polo kinases - Google Patents

Souches de levure permettant d'identifier des inhibiteurs specifiques de polo kinases Download PDF

Info

Publication number
WO2001090401A2
WO2001090401A2 PCT/US2001/016903 US0116903W WO0190401A2 WO 2001090401 A2 WO2001090401 A2 WO 2001090401A2 US 0116903 W US0116903 W US 0116903W WO 0190401 A2 WO0190401 A2 WO 0190401A2
Authority
WO
WIPO (PCT)
Prior art keywords
polo
cell
box
kinase
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/016903
Other languages
English (en)
Other versions
WO2001090401A3 (fr
Inventor
Kyung S. Lee
Sukgil Song
Raymond Erikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Harvard University
US Department of Health and Human Services
Original Assignee
National Institutes of Health NIH
Harvard University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, Harvard University, US Department of Health and Human Services filed Critical National Institutes of Health NIH
Priority to AU2001263418A priority Critical patent/AU2001263418A1/en
Publication of WO2001090401A2 publication Critical patent/WO2001090401A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001090401A3 publication Critical patent/WO2001090401A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • FIELD This disclosure relates to methods of identifying and using compounds and peptides that interact with a kinase or kinase target protein, particularly a polo kinase, as well as such compounds and peptides.
  • Such compounds can be, for instance, inhibitors of a kinase.
  • BACKGROUND Cancer is a genetic disease caused by alterations in the genes controlling the cell cycle.
  • polo kinase subfamily members are characterized by the presence of a distinct region of homology in the C-terminal non-catalytic domain, termed the polo-box (Clay et al, Proc. Natl. Acad. Sci. USA. 90:4882-4886, 1993).
  • polo-box a distinct region of homology in the C-terminal non-catalytic domain.
  • Studies in various organisms have shown that polo kinases regulate diverse cellular and biochemical events at multiple stages of M phase (mitosis). In addition to their function in mitosis, some evidence supports a theory that polo kinases may play an important but undefined role in cytokinesis (see reviews, Fishkind and Wang, Cnrr. Opin. Cell Biol. 7:23-31, 1995; and Field et al, Curr. Opin. Cell Biol. 11 :68-80, 1999).
  • Cytokinesis is preceded by inactivation of cyclin-dependent kinase Cdc2 (not a polo-like kinase).
  • Cdc2 cyclin-dependent kinase
  • APC anaphase-promoting complex
  • the Cdc5 gene has been identified in the budding yeast S. cerevisiae as encoding a polo-like kinase.
  • a cdc5-l temperature sensitive mutant arrests at late mitosis at the restrictive temperature, and exhibits reduced APC activity. Overexpression of the Cdc5 protein results in an increased APC activity.
  • Cdc5 Although the role of Cdc5 in the mitotic exit pathway is well established, it is not known if Cdc5 activity is required for cytokinesis. There are no identified cdc5 mutants that exhibit a cytokinetic defect without inhibiting mitotic exit.
  • the disclosed methods take advantage of the finding that ectopic expression of a polo-box in a eukaryotic cell causes a severe cytokinetic defect in the cell.
  • Methods are described herein that use this effect to isolate compounds that modify polo-like kinase function, for instance by inhibiting or enhancing the binding of a polo-box region of a polo-like kinase to a target molecule (e.g., receptor or other specific binding partner).
  • a target molecule e.g., receptor or other specific binding partner
  • Compounds that modify polo-like kinase expression and/or function can be used in the treatment of different diseases or conditions, including hyper- proliferative disorders such as a neoplasm.
  • Certain disclosed embodiments are methods of identifying a compound with polo-like kinase modulating activity. These methods involve contacting a eukaryotic cell that exhibits a dominant negative cytokinesis-defective growth pattern with a test compound and assessing an effect of the test compound on the cell.
  • the eukaryotic cells express at least one of the following: (a) a polo-box or polo-box related peptide; (b) a binding peptide comprising at least 25 residues from a polo-like kinase C-terminal region; or (c) a functional fragment, variant, mimetic, or analog of the peptide of (a) or (b).
  • an effect of the test compound may include an observed alteration in the growth pattern of the eukaryotic cell, or a subcellular localization of a polo-like kinase (e.g., its association with neck filament proteins, such as septins, or with spindle pole components, including Bbpl or Mps2), or a measurable phosphorylation activity of a polo-like kinase.
  • a polo-like kinase e.g., its association with neck filament proteins, such as septins, or with spindle pole components, including Bbpl or Mps2
  • Another embodiment includes further assessing a compound identified by one of the disclosed methods for anti-neoplastic activity (e.g., the ability of the compound to reduce growth of a cancer cell).
  • Also encompassed herein are methods for modifying a polo-like kinase function e.g., a mitotic and/or cytokinetic function
  • a eukaryotic cell is contacted with a substance that alters (either enhancing or inhibiting) a specific interaction between a polo-box and a polo-box specific binding partner.
  • binding partners include elements of neck-filaments and elements of spindle pole bodies. Substances used in these methods are further embodiments.
  • these methods of modifying a polo kinase function are methods for treating a hyper-proliferative disorder (e.g., a neoplasm, such as a cancer) in a subject in need of such treatment.
  • a hyper-proliferative disorder e.g., a neoplasm, such as a cancer
  • the substance can be applied to the eukaryotic cell in a pharmaceutically acceptable carrier.
  • the expressed heterologous nucleic acid can encode, for instance, a polo-box, or a functional fragment, variant, mimetic, or analog thereof. In certain embodiments, however, the heterologous nucleic acid does not encode a kinase with substantial kinase activity.
  • the eukaryotic cells produced by these methods are further embodiments provided herein.
  • kits for the treatment of a hyper-proliferative disorder include a therapeutic substance that inhibits binding of a polo-box to a polo-box binding partner. Some such kits will also include instructions (e.g., directions for administering at least one dose of the therapeutic substance to a subject in need of such treatment).
  • the therapeutic substance in the disclosed kits may be provided in the form of a pharmaceutical composition.
  • Specific examples of substances that can be included in these kits are the disclosed compounds with polo-like kinase modulatory activity or with polo-box modulatory activity and those that alter specific interactions between a polo-box and a polo-box specific binding partner.
  • Eukaryotic cells include fungal, animal, and plant cells. Specific examples include human cells or yeast cells. Specific yeast cells include cells of the yeast S. cerevisiae, such as those carrying a mutation in either a cyk2 or a myol encoding sequence. In specific embodiments wherein the eukaryotic cell is a yeast cell, the yeast cells are of strain KLY1083 or KLY1212.
  • Polo-boxes include those that contain the sequence of SEQ ID NO: 1, and functional fragments or variant thereof.
  • the polo-box corresponds to that of a polo-like kinase (e.g., Cdc5, Polo, Plkl raaramal ⁇ an , Plolp, Snk, FNK/Prk, Pb l, Tbplk, Plkl c elegans ).
  • Particular specific examples include polo-boxes that correspond to those found in Cdc5 or mammalian Plk.
  • a specific embodiment disclosed herein is a method of specifically inhibiting certain mitotic functions of polo kinases (such as their role in cytokinesis, e.g., in budding yeast) without substantially inhibiting mitosis.
  • This method involves exposing a cell to a substance that inhibits a specific interaction between a polo-box and its binding partner(s) (such as septins Cdcl 1 or 12, Bbpl and/or Mps2), wherein the substance does not have assayable protein phosphorylation activity.
  • Another specific embodiment is a method of specifically inhibiting cytokinesis without substantially inhibiting mitosis. This method involves exposing a cell to a substance that inhibits a specific interaction between a polo-box and a septin, wherein the substance does not have assayable protein phosphorylation activity.
  • nucleic acid and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and the three-letter code for amino acids. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood to be included by any reference to the displayed strand.
  • SEQ ID NO: 1 shows the consensus amino acid sequence of a polo-box.
  • FIG 1A and IB show a time course of the expression level of HA-tagged fusion polo- family protein in two yeast strains, and the proportion of cells arrested at different at various points of the cell cycle.
  • Depletion of Plk or cdc5-l protein revealed a large fraction of large-budded cells with disassembled spindles.
  • Strains KLY1046 (expressing GAL1-HA-EGFP-PLK) and KLY1047 (expressing GALl-HA-EGFP-cdc5-l) growing exponentially in YEP-galactose medium were transferred into YEP-glucose to deplete Plk and cdc5-l proteins.
  • FIG 2 shows a western blot of cell extracts from a control and cells expressing a functional (cdc5AN) or localization-defective (cdc5AN /FAA) C-terminal region of Cdc5, showing that the FAA mutations in the polo-box do not influence the level of cdc5 AN expression.
  • An equal amount (30 ⁇ g) of cell lysate prepared from various strains shown in panel A was loaded onto each lane.
  • FIG 3A shows two graphs illustrating that strain KLY1083 (expressing EGFP-cdc5AN) grows without increasing cell numbers under the induction conditions.
  • Cells expressing control EGFP (KLY1080), EGFP-cdc5AN (KLYX0S3), or EGFP-cdc5AN/FAA (KLY1229) were taken at the indicated time points upon transferring cultures into YEP-galactose.
  • Cell number was determined by plating serial dilutions on YEP-glucose and counting the colony numbers. The number of cells at time 0 was 1.2 x 10 6 cells per ml with an OD 600 of 0.05. The resulting cell number and OD 600 at each time point were divided by those at time 0 to give relative cell number and OD 600 .
  • FIG 3B shows the relative quantity (by Western blot) of EGFP-cdc5 ⁇ N protein in strains expressing the indicated fusions; the FAA mutations do not influence the stability of EGFP-cdc5 ⁇ N.
  • EGFP-cdc5 ⁇ N was detected by an anti-GFP antibody, whereas Cdc28 (loading control) was recognized by an anti-Cdc28 antibody.
  • IX one copy of cdc5 AN
  • 3X three copies of cdc5AN.
  • FIG 4 is a table of the interactions between the indicated constructs in a two hybrid system, and the structures of various Cdc5 constructs used in these analyses.
  • a destruction-box deficient form of Cdc5 (Song et al, Mol Cell. Biol. 20:286-298, 2000) was used in place of the wild-type Cdc5.
  • Grey boxes indicate the kinase domain in the N-terminus of Cdc5.
  • cdc5 ⁇ C C-terminal domain deletion
  • cdc5 ⁇ N N-terminal domain deletion
  • cdc5 ⁇ N/FAA N- terminal domain deletion with FAA mutations in the polo-box
  • a and b control plasmids: pEG202- NLS (DBD fusion vector) and pJG4-5 (AD fusion vector).
  • FIG 5 shows a comparison of the amino acid sequences of the mammalian polo-like kinase Plk (query) and the yeast Cdc5 (subject).
  • the polo-box consensus is at amino acid residues 410 to 430 in Plk.
  • FIG 6 is a schematic drawing of a budding yeast cell, showing the interactions or lack of interactions of the indicated polo-like kinase molecules and derived proteins with specific binding proteins (represented by a gray circle marked with an "X").
  • Endogenous Cdc5 has both an N-terminal kinase domain (K.D.) and a C-terminal polo box (P.B.); interactions of this molecule with at least some of its specific binding partners are mediated by the polo domain.
  • the polo box expressed on its own (marked as WT), can also interact with these specific binding partners such as septins at the neck filaments and Bbpl at the spindle poles.
  • a binding-incompetent version of a polo box (marked FAA, indicative of point-mutated amino acids within the polo box consensus sequence) cannot specifically interact with polo-box binding proteins.
  • FIG 7 is a series of schematic drawings of polo-box action during cytokinesis, and models for compound interactions that disrupt this action.
  • Wild type yeast express Cdc5 (a polo-like kinase, PLK) and at least one cytokinesis-linked specific binding partner, referred to here as a "target" (FIG 7A).
  • Cdc5 a polo-like kinase, PLK
  • target cytokinesis-linked specific binding partner
  • FIG. 7A At some point prior to cytokinesis, at least a portion of the Cdc5 molecules within the cell relocates to the bud neck; this localization is mediated by the interaction between the polo-box and at least one specific binding partner such as septins (Cdcl 1 and Cdcl2) (FIG 7B). Relocalization of the Cdc5 to the bud neck (at the neck filament complex) permits initiation of cytokinesis that leads to the separation of the mother and
  • FIG 7D illustrates the dominant negative effect of over-expressing a polo-box peptide.
  • ectopically expressed polo box competes for native polo-like kinase for binding sites at the bud neck.
  • Insufficient native kinase e.g., Cdc5
  • Cdc5 native kinase
  • FIG 7E illustrates more generally that non-polo-box substances can be used to compete for receptor binding sites at the bud neck.
  • a substance either peptide or non- peptide
  • receptor a polo-box specific binding partner
  • inhibiting substance will prevent enough of the kinase from re-localizing to the bud neck that cytokinesis is blocked.
  • FIG 7F illustrates the action of substance that interacts with the polo-box itself, thereby inhibiting the cytokinesis-related functions of the polo box.
  • the native polo kinase cannot interact with its neck filament receptor(s), and therefore does not re-locate to the bud neck. In the absence of such re-localization, these cells cannot complete cytokinesis.
  • FIG 8 is a series of schematic drawings, illustrating the disclosed method of isolating compounds by complementation of the polo-box over-expression dominant negative phenotype.
  • FIG 8A shows a eukaryotic cell (e.g., a yeast cell) expressing a polo-box peptide. Because the ectopically expressed polo-box competes for binding at the mother-bud neck, this cell is arrested and cytokinesis (FIG 8B) cannot complete.
  • a eukaryotic cell e.g., a yeast cell
  • cytokinesis FIG 8B
  • FIG 8C shows that the addition of a compound that binds to a polo-box can overcome this dominant negative cytokinetic arrest.
  • This compound is referred to generally as an "inhibitor" or
  • binding inhibitor Depending on the number of polo kinase molecules and ectopically expressed polo boxes there are in the cell, an amount of the binding inhibitor molecule will "scavenge" sufficient of the over-expressed polo-boxes to allow the polo kinase to re-locate to the mother-bud neck specific binding partner(s), thereby rescuing the arrest phenotype.
  • the amount of the inhibitor compound necessary to overcome arrest will be influenced also by its relative affinity for the polo
  • the compound when a compound with these characteristics is applied to a wild- type cell (not over-expressing a polo-box), the compound inhibits re-location of the native kinase to the mother-bud neck, and thereby inhibits cytokinesis.
  • FIG 9 shows a schematic representation of four deletion variants of Plk (FIG 9A), and a
  • FIG 9B 40 Western blot showing expression of these constructs in HEK293 cells.
  • the diagram shows four constructs expressing different regions of the Plk coding sequence.
  • Construct #1 and #3 are two different versions of the C-terminal domain of Plk, whereas construct #2 and #4 lack polo-box 2 and polo-box 3 of #1 and #3, respectively.
  • Recombinant HA-GFP-Plk was generated by N-terminally tagging Plk with HA (hemagglutinin epitope) and GFP (green fluorescence protein).
  • Adenoviral expression constructs bearing various forms of HA-GFP-PLK cDNA were expressed in HEK293 cells using the pAdEasy-1 expression system (He, Proc. Natl. Acad. Sci., USA, 1998. 95:2509-2514). Expression of these proteins was detected with anti-HA antibody using enhanced chemiluminiscence Western analysis.
  • FAA shorthand designation for the triple mutation W517F/V518A/L530A in a polo-box
  • EGFP enhanced green fluorescent protein
  • plk polo-like kinase
  • Analog, derivative or mimetic An analog is a molecule that differs in chemical structure from a parent compound, for example a homolog (differing by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, a change in ionization. Structural analogs are often found using quantitative structure activity relationships (QSAR), with techniques such as those disclosed in Remington (The Science and Practice of Pharmacology, 19th Edition (1995), chapter 28).
  • a derivative is a biologically active molecule derived from the base structure.
  • a mimetic is a biomolecule that mimics the activity of another biologically active molecule. Biologically active molecules can include both chemical structures and peptides of protein entities that mimic the biological activities of the compounds or peptides.
  • Animal Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds.
  • mammal includes both human and non-human mammals.
  • subject includes both human and veterinary subjects.
  • Anti-proliferative activity An activity of a molecule, e.g. , a compound or peptide as described herein, which reduces proliferation of at least one cell type, but which may reduce the proliferation (either in absolute terms or in rate terms) of multiple different cell types (e.g., different cell lines, different species, etc.).
  • the anti-proliferative activity will be apparent against cells (either in vitro or in vivo) that exhibit a hyper-proliferative condition, such as is characteristic of certain disorders or diseases.
  • an anti-proliferative activity can be an anti-tumor or anti-neoplastic activity of a compound or peptide.
  • Such molecules will be useful to inhibit or prevent cellular proliferation or growth, e.g. in a tumor, such as a malignant neoplasm.
  • Double-stranded DNA has two strands, a 5'— >
  • RNA polymerase adds nucleic acids in a 5' — > 3' direction, the minus strand of the DNA serves as the template for the RNA during transcription.
  • the RNA formed will have a sequence complementary to the minus strand and identical to the plus strand (except that U is substituted for T).
  • Antisense molecules are molecules that are specifically hybridizable or specifically complementary to either RNA or the plus strand of DNA.
  • Sense molecules are molecules that are specifically hybridizable or specifically complementary to the minus strand of DNA.
  • Antigene molecules are either antisense or sense molecules directed to a dsDNA target.
  • Binding or stable binding An oligonucleotide binds or stably binds to a target nucleic acid if a sufficient amount of the oligonucleotide forms base pairs or is hybridized to its target nucleic acid, to permit detection of that binding. Binding can be detected by either physical or functional properties of the target: oligonucleotide complex. Binding between a target and an oligonucleotide can be detected by any procedure known to one skilled in the art, including both functional and physical binding assays. Binding may be detected functionally by determining whether binding has an observable effect upon a biosynthetic process such as expression of a gene, DNA replication, transcription, translation and the like.
  • Physical methods of detecting the binding of complementary strands of DNA or RNA are well known in the art, and include such methods as DNAse I or chemical footprinting, gel shift and affinity cleavage assays, Northern blotting, dot blotting and light absorption detection procedures.
  • DNAse I or chemical footprinting gel shift and affinity cleavage assays
  • Northern blotting dot blotting
  • light absorption detection procedures For example, one method that is widely used, because it is so simple and reliable, involves observing a change in light absorption of a solution containing an oligonucleotide (or an analog) and a target nucleic acid at 220 to 300 nm as the temperature is slowly increased. If the oligonucleotide or analog has bound to its target, there is a sudden increase in absorption at a characteristic temperature as the oligonucleotide (or analog) and target disassociate from each other, or melt.
  • T m The binding between an oligomer and its target nucleic acid is frequently characterized by the temperature (T m ) at which 50% of the oligomer is melted from its target.
  • T m the temperature at which 50% of the oligomer is melted from its target.
  • a higher (T m ) means a stronger or more stable complex relative to a complex with a lower (T m ).
  • Binding inhibitory amount An amount of a substance sufficient to inhibit, to some measurable extent, the binding of one substance to another.
  • at least one of the substances in a complex for which binding inhibition is being studied will be a protein, a peptide, or a fragment, mimetic, analog or derivative thereof.
  • such a complex may include a polo-like kinase and one (or more) of its cognate "receptor" molecules, for instance a protein that interacts with the kinase by way of a polo-box region within the kinase.
  • a binding inhibitory amount of a substance for instance, a peptide or other compound
  • a substance for instance, a peptide or other compound
  • the "receptor" molecule for a polo-like kinase will be a protein involved in cytokinesis, for instance a neck filament protein (such as a septin, as described herein).
  • a binding inhibitory amount of a substance is merely an amount sufficient to disrupt some of the binding between two molecules, or two populations of molecules, and is not intended to be an absolute term. However, in certain embodiments a binding inhibitory amount of a substance will be an amount necessary to disrupt at least about 30% of the specific association between two molecules. In other embodiments, it will be an amount sufficient to disrupt at least about 40%, about 50%, about 60%, about 70%, or about 80% of such specific binding. Under some circumstances, binding inhibitory amounts will be sufficient to inhibit an even greater proportion of the binding between two molecules, and may be as high as at least about 90%, 95%, or even 98%. Such particularly high levels of binding inhibition are not required in all circumstances, however.
  • cDNA complementary DNA: A piece of DNA lacking internal, non-coding segments (introns) and transcriptional regulatory sequences. cDNA may also contain untranslated regions (UTRs) that are responsible for translational control in the corresponding RNA molecule. cDNA is usually synthesized in the laboratory by reverse transcription from messenger RNA extracted from cells.
  • a growth pattern in a eukaryote, particularly a yeast (e.g., S. cerevisiae) wherein cytokinesis is inhibited to an extent sufficient to prevent a proportion of mature daughter cells from cleaving completely from the mother cell.
  • yeast e.g., S. cerevisiae
  • the chaining (connected) growth pattern is typified by yeast strains that over-express a C- terminal peptide that contains a polo-box from a polo-like kinase. Several such strains are described herein in detail.
  • Complementarity and percentage complementarity Molecules with complementary nucleic acids form a stable duplex or triplex when the strands bind, (hybridize), to each other by forming Watson-Crick, Hoogsteen or reverse Hoogsteen base pairs. Stable binding occurs when an oligonucleotide remains detectably bound to a target nucleic acid sequence under the required conditions.
  • Complementarity is the degree to which bases in one nucleic acid strand base pair with the bases in a second nucleic acid strand. Complementarity is conveniently described by percentage, i.e. the proportion of nucleotides that form base pairs between two strands or within a specific region or domain of two strands. For example, if 10 nucleotides of a 15-nucleotide oligonucleotide form base pairs with a targeted region of a DNA molecule, that oligonucleotide is said to have 66.67% complementarity to the region of DNA targeted.
  • “Sufficient complementarity” means that a sufficient number of base pairs exist between the oligonucleotide and the target sequence to achieve detectable binding, and in the case of the binding of an antigen, disrupt expression of gene products (such as a polo-like kinase). When expressed or measured by percentage of base pairs formed, the percentage complementarity that fulfills this goal can range from as little as about 50% complementarity to full, (100%) complementary. In general, sufficient complementarity is at least about 50%, about 75% complementarity, about 90% or 95% complementarity, and or about 98% or even 100% complementarity.
  • association can be measured in any of various ways, both direct and indirect.
  • Direct methods may include co-migration in non-denaturing fractionation conditions, for instance.
  • Indirect measurements of association will depend on secondary effects caused by the association of the two proteins or protein domains. For instance, the formation of a complex between a kinase and a receptor or localization anchor may be demonstrated by an alteration in the subcellular localization of the kinase, or a consequent growth defect (e.g., a cytokinesis-defective growth pattern).
  • the formation of a complex between a polo-like kinase (or a polo-box peptide) and a compound with polo-like kinase modulating activity can be measured by determining the degree to which the compound alters a cytokinesis-defective growth pattern in a cell expressing a polo-box domain of a polo-like kinase.
  • the inhibitory activity of the compound will be proportional to the extent to which the compound inhibits cytokinesis.
  • the inhibitory activity of such a compound can be measured as the extent of recovery from a cytokinesis-defective phenotype of a cell over-expressing a polo-box domain (e.g., a reduction in the proportion of chained cells in a yeast system).
  • activity of the compound can be measured by an intensification of a cytokinesis-defect observed in a cell over-expressing a polo-box domain (e.g., an increase in the proportion of chained cells in a yeast system).
  • Compound with polo-like kinase modulatory activity A compound that, when applied to a cell or cell free system, has a measurable effect on a polo-like kinase.
  • effects include any or all of the following: a modification in the subcellular localization of the polo-like kinase; a modification in binding affinity of polo-domain or the polo-box (or related peptide) for one or more specific binding partners; a change in the phosphorylating activity of the kinase; or an alteration (either stimulation or inhibition) in the stability of the polo-like kinase.
  • Cytokinesis-defective growth pattern A growth pattern or phenotype that is measurably abnormal as a result of a defect in a cell's ability to progress through cytokinesis (cell division of, for instance, a daughter cell from its mother).
  • cytokinesis-defective growth pattern is exhibited by yeast cells that over-express a functional copy of a polo-box (e.g., one sharing substantial sequence homology with the Cdc5 polo-box), thereby having an inhibition in polo-like kinase mediated cytokinesis events.
  • yeast cells form chains of connected cells, wherein cytokinesis has begun but is unable to finish.
  • Such cultures produce branched, filamentous cell chains, for instance as illustrated in Song and Lee, "A Novel Function of Saccharomyces cerevisiae CDC 5 in Cytokinesis," J. Cell Biol. 152:451-470, February 5, 2001, incorporated herein by reference in its entirety.
  • Mammalian cells exhibit a different growth pattern in response to introduction of an over expressed polo-box.
  • mammalian cells exhibit a mitotic arrest with a rounded phenotype. Since over-expression of polo box induces multiple spindle poles by interaction with Bbpl in budding yeast, the rounded phenotype see in mammalian cell culture suggests that in mammalian cells polo box function is also required for an essential event prior to cytokinesis (such as centromere maturation).
  • DNA deoxyribonucleic acid
  • DNA is a long chain polymer which comprises the genetic material of most living organisms (some viruses have genes comprising ribonucleic acid (RNA)).
  • the repeating units in DNA polymers are four different nucleotides, each of which comprises one of the four bases, adenine, guanine, cytosine and thymine bound to a deoxyribose sugar to which a phosphate group is attached.
  • codons Triplets of nucleotides (referred to as codons) code for each amino acid in a polypeptide, or for a stop signal.
  • codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the DNA sequence is transcribed.
  • any reference to a DNA molecule is intended to include the reverse complement of that DNA molecule. Except where single-strandedness is required by the text herein, DNA molecules, though written to depict only a single strand, encompass both strands of a double-stranded DNA molecule. Thus, a reference to the nucleic acid molecule that encodes a pololike kinase, or a fragment thereof (e.g., a polo-box), encompasses both the sense strand and its reverse complement. Thus, for instance, it is appropriate to generate probes or primers from the reverse complement sequence of the disclosed nucleic acid molecules. Deletion: The removal of a sequence of DNA, the regions on either side of the removed sequence being joined together. Correspondingly, a deletion in a protein is the removal of a region of amino acid sequence of the protein or peptide.
  • Dominant negative phenotype A phenotype resulting form inhibiting endogenous protein function by expression of a protein, or a competing peptide.
  • the term implies competition between the native protein and the expressed protein/peptide for a binding site.
  • the term as used herein more specifically refers to the effect of expressing or over- expressing a polo-box (or related peptide) in a eukaryotic cell and thereby blocking association of native polo-like kinase with one or more specific binding partners essential for their mitotic and/or cytokinetic functions, through competition for one or more polo-box specific binding site(s).
  • This phenotype is illustrated, for instance, in FIG 7B.
  • the phenotype is "dominant” in that it is apparent in cells that are expressing a native polo-like kinase, and "negative” in that it causes a recognizable growth defect (definable cell cycle arrest).
  • Genomic target sequence A sequence of nucleotides located in a particular region in the human genome that corresponds to one or more specific genetic abnormalities, such as a nucleotide polymorphism, a deletion, or an amplification.
  • the target can be for instance a coding sequence; it can also be the non-coding strand that corresponds to a coding sequence.
  • nucleic acid consists of nitrogenous bases that are either pyrimidines (cytosine (C), uracil (U), and thymine (T)) or purines (adenine (A) and guanine (G)). These nitrogenous bases form hydrogen bonds between a pyrimidine and a purine, and the bonding of the pyrimidine to the purine is referred to as "base pairing.” More specifically, A will hydrogen bond to T or U, and G will bond to C.
  • “Complementary” refers to the base pairing that occurs between to distinct nucleic acid sequences or two distinct regions of the same nucleic acid sequence.
  • “Specifically hybridizable” and “specifically complementary” are terms that indicate a sufficient degree of complementarity such that stable and specific binding occurs between the oligonucleotide (or its analog) and the DNA or RNA target.
  • the oligonucleotide or oligonucleotide analog need not be 100% complementary to its target sequence to be specifically hybridizable.
  • An oligonucleotide or analog is specifically hybridizable when binding of the oligonucleotide or analog to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide or analog to non-target sequences under conditions where specific binding is desired, for example under physiological conditions in the case of in vivo assays or systems. Such binding is referred to as specific hybridization.
  • Hybridization conditions resulting in particular degrees of stringency will vary depending on the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially the Na + concentration) of the hybridization buffer will determine the stringency of hybridization, though waste times also influence stringency. Calculations regarding hybridization conditions required for attaining particular degrees of stringency are discussed by Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, chapters 9 and 11, herein incorporated by reference.
  • stringent conditions encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence.
  • Stringent conditions may be broken down into particular levels of stringency for more precise definition.
  • “moderate stringency” conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of “medium stringency” are those under which molecules with more than 15% mismatch will not hybridize, and conditions of “high stringency” are those under which sequences with more than 10% mismatch will not hybridize.
  • Conditions of "very high stringency” are those under which sequences with more than 6% mismatch will not hybridize.
  • Hyper-proliferative disorder A disorder characterized by abnormal proliferation of cells, and generically includes skin disorders such as psoriasis as well as benign and malignant tumors of all organ systems.
  • This latter class of hyper proliferative disorder includes, for instance, breast carcinomas (including lobular and duct carcinomas) and other solid tumors, carcinomas, sarcomas, and cancers including carcinomas of the lung like small cell carcinoma, large cell carcinoma, squamous carcinoma, and adenocarcinoma, mesothelioma of the lung, colorectal adenocarcinoma, stomach carcinoma, prostatic adenocarcinoma, ovarian carcinoma such as serous cystadenocarcinoma and mucinous cystadenocarcinoma, ovarian germ cell tumors, testicular carcinomas, and germ cell tumors, pancreatic adenocarcinoma, biliary adenocarcinoma, heptacellular carcinoma, bladder carcinoma including transitional
  • a pharmaceutically acceptable fluid composition comprising at least one active ingredient, e.g., a compound with polo-like kinase modulatory activity, a polo-box related peptide, or a polo-box binding peptide.
  • the active ingredient is usually dissolved or suspended in a physiologically acceptable carrier, and the composition can additionally comprise minor amounts of one or more non-toxic auxiliary substances, such as emulsifying agents, preservatives, and pH buffering agents and the like.
  • Such injectable compositions that are useful for use with the compounds and peptides of this disclosure are conventional; formulations are well known in the art.
  • Isolated An "isolated" biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, i.e., other chromosomal and extra- chromosomal DNA and RNA, proteins and organelles.
  • Nucleic acids and proteins that have been "isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • Kinase An enzyme that transfers a phosphate group, usually from ATP.
  • Kinase (phosphorlylating) activity Measurable phosphorylating activity of a protein (a kinase).
  • Kinase activity can be quantified using well known assays (see, e.g., Jaspersen et ⁇ l, Mo. Biol. Cell, 9:2803-2817, 1998), which measure, for instance, incorporation of a radioactive isotope of phosphorous into a test compound (e.g., incorporation of [ ⁇ - 32 P] from [ ⁇ - 32 P]ATP into a protein with a known phosphorylation site).
  • kinase activity can be measured by the degree of autophosphorylation or on the basis of a phosphorylation-dependent protein mobility shift.
  • Mimetic A molecule (such as an organic chemical compound) that mimics the activity of a protein or peptide, such as the specific binding activity of a polo-box peptide.
  • Peptidomimetic and organomimetic embodiments are within the scope of this term, whereby the three-dimensional arrangement of the chemical constituents of such peptido- and organomimetics mimic the three- dimensional arrangement of the peptide backbone and component amino acid sidechains in the peptide, resulting in such peptido- and organomimetics of the peptides having substantial specific inhibitory activity.
  • a pharmacophore is an idealized, three- dimensional definition of the structural requirements for biological activity.
  • Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (using computer assisted drug design or CADD). See Walters, ("Computer-Assisted Modeling of Drugs” in Klegerman & Groves, eds., 1993, Pharmaceutical Biotechnology, Interpharm Press: Buffalo Grove, IL, pp. 165-174 and Principles of Pharmacology (ed. Munson, 1995), chapter 102) for a description of techniques used in computer assisted drug design.
  • Neck filament components Molecular components of the structures involved in cytokinesis, e.g., in a yeast cell.
  • Neck filament components include, for instance, septins (such as Cdc3, CdclO, Cdcl 1, and Cdcl2).
  • septins such as Cdc3, CdclO, Cdcl 1, and Cdcl2.
  • Data reported herein indicate that the polo-box of polo-like kinases is required for localization of this protein to the bud neck during cytokinesis.
  • This cytokinesis-associated localization of at least a sub-population of polo-like kinase molecules in a cell to the neck filaments may indicate that a direct interaction between polo-box peptide and a septin occurs, and is essential for completion of cytokinesis.
  • Nucleotide includes, but is not limited to, a monomer that includes a base linked to a sugar, such as a pyrimidine, purine or synthetic analogs thereof, or a base linked to an amino acid, as in a peptide nucleic acid (PNA).
  • a nucleotide is one monomer in a polynucleotide.
  • a nucleotide sequence refers to the sequence of bases in a polynucleotide.
  • Oligonucleotide is a plurality of joined nucleotides joined by native phosphodiester bonds, between about 6 and about 300 nucleotides in length.
  • An oligonucleotide analog refers to moieties that function similarly to oligonucleotides but have non-naturally occurring portions.
  • oligonucleotide analogs can contain non-naturally occurring portions, such as altered sugar moieties or inter-sugar linkages, such as a phosphorothioate oligodeoxynucleotide.
  • Functional analogs of naturally occurring polynucleotides can bind to RNA or DNA, and include peptide nucleic acid (PNA) molecules.
  • PNA peptide nucleic acid
  • oligonucleotides and oligonucleotide analogs can include linear sequences up to about 200 nucleotides in length, for example a sequence (such as DNA or RNA) that is at least 6 bases, for example at least 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100 or even 200 bases long, or from about 6 to about 50 bases, for example about 10-25 bases, such as 12, 15 or 20 bases.
  • Operably linked A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence.
  • operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
  • Open reading frame A series of nucleotide triplets (codons) coding for amino acids without any internal termination codons. These sequences are usually translatable into a peptide.
  • Ortholog Two nucleic acid or amino acid sequences are orthologs of each other if they share a common ancestral sequence and diverged when a species carrying that ancestral sequence split into two species. Orthologous sequences are also homologous sequences.
  • parenteral Administered outside of the intestine, e.g., not via the alimentary tract.
  • parenteral formulations are those that will be administered through any possible mode except ingestion. This term especially refers to injections, whether administered intravenously, intrathecally, intramuscularly, intraperitoneally, or subcutaneously, and various surface applications including intranasal, intradermal, and topical application, for instance.
  • PNA Peptide Nucleic Acid
  • PNA An oligonucleotide analog with a backbone comprised of monomers coupled by amide (peptide) bonds, such as amino acid monomers joined by peptide bonds.
  • Pharmaceutical agent or drug A chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
  • compositions and formulations suitable for pharmaceutical delivery of the proteins and other compositions herein disclosed are conventional. Remington 's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the proteins and other compositions herein disclosed.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
  • solid compositions e.g., powder, pill, tablet, or capsule forms
  • conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
  • compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Polo-like kinase A member of a family of kinase proteins that are characterized by the presence of a distinct region of homology in the C-terminal non-catalytic domain of the kinase. This domain is termed the polo-box, and it appears (as reported herein) to be important for subcellular localization of polo-like kinase proteins.
  • the name of this family of kinases is derived form the polo ⁇ . gene, which encodes the first polo-like kinase identified; polo is a Drosophila gene.
  • polo subfamily of protein kinases e.g., Cdc5, Polo, Plkl raamraanan , Plolp, Snk, FNK/Prk, Plxl, Tbplk, and Plkl c elegans
  • Cdc5 polo subfamily of protein kinases
  • Polo Plkl raamraanan , Plolp, Snk, FNK/Prk, Plxl, Tbplk, and Plkl c elegans
  • PLC anaphase promoting complex
  • sequences of polo-lik kinases include those disclosed in the following GenBank Accession Nos.: P32562 (S. cerevisiae Cdc5); P53351 (M. musculus Snk); P50528 (S. pombe Plol); P52304 (D. melanogaster Polo); P34331 (C elegans Ykz4); P53350 (H. sapiens Plkl); Q07832 (M. musculus Plkl); and CAA02714 (H. sapiens serine-threonine kinase). These sequences are incorporated herein by reference.
  • Polo-box A distinct region of homology in the C-terminal non-catalytic domain of a pololike kinase. This domain appears (as reported herein) to be important for subcellular localization of these kinases.
  • the core sequence of a polo-box (corresponding to residues 513 through 542 of Cdc5 and residues 410 through 439 of mammalian Plk) is as follows:
  • a polo-box (related) peptide is a linear sequence of amino acids, usually longer than the consensus sequence depicted in SEQ ID NO: 1, that is capable, of competing with a native polo-box for binding to or specific association with at least one specific binding partner (target) of the native polo-box.
  • a peptide contains at least 25 residues from a polo-like kinase C-terminal region, or a functional (e.g., binding functional) variant, analog, or mimetic thereof.
  • a polo-box related peptide can include further linear amino acid sequences upstream and/or downstream of the core consensus box.
  • the length of any additional amino acid sequence does not need to be the same on the upstream and downstream sides of the consensus box.
  • Additional amino acid sequences can be from a native polo-like kinase (as in certain of the specific examples disclosed herein), or they can be sequences taken from other proteins or purely or partially random or other non-naturally occurring amino acid sequences.
  • One possible purpose for the addition of additional up- and/or downstream sequences in a polo-box peptide is to provide stability of the peptide in a biological system (e.g., a cell or the body of a subject).
  • these additional sequences of amino acids can serve to tag the peptide in order to enable tracking and localization (e.g., with a green fluorescent protein, as described herein, or with an epitope or other peptide tag), to target the peptide to specific cells or tissues (e.g., through interaction of a targeting or binding domain to a receptor, especially when the peptide is applied to a subject as a pharmaceutical preparation rather than through gene therapy), or for other purposes.
  • Functional fragments and variants of a polo-box are those peptide sequences share sequence homology with a native polo-box domain, but have one or more sequence change (for instance, a conservative residue change, deletion, addition and so forth), and still maintain a polo-box functional activity (e.g., a binding activity or other activity as described herein).
  • Primers are short nucleic acid molecules, for instance DNA oligonucleotides 10 nucleotides or more in length. Longer DNA oligonucleotides may be about 15, 20, 25, 30 or 50 nucleotides or more in length. Primers can be annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then the primer extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR) or other nucleic-acid amplification methods known in the art. Methods for preparing and using nucleic acid primers are described, for example, in
  • Amplification primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, ⁇ 1991, Whitehead Institute for Biomedical Research, Cambridge, MA).
  • Primer Version 0.5, ⁇ 1991, Whitehead Institute for Biomedical Research, Cambridge, MA.
  • a probe comprises an isolated nucleic acid attached to a detectable label or other reporter molecule.
  • Typical labels include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes. Methods for labeling and guidance in the choice of labels appropriate for various purposes are discussed, e.g., Sambrook et al. (In Molecular Cloning: A Laboratory Manual, CSHL, New York, 1989) and Ausubel et al. (In Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1998).
  • a promoter is an array of nucleic acid control sequences that direct transcription of a nucleic acid.
  • a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element.
  • a promoter also optionally includes distal enhancer or repressor elements that can be located as much as several thousand base pairs from the start site of transcription.
  • Protein A biological molecule expressed by a gene and comprised of amino acids.
  • purified does not require absolute purity; rather, it is intended as a relative term.
  • a purified protein preparation is one in which the protein referred to is more pure than the protein in its natural environment within a cell or within a production reaction chamber (as appropriate).
  • a recombinant nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.
  • Sequence identity The similarity between two nucleic acid sequences, or two amino acid sequences, is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are.
  • NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al. J. Mol. Biol. 215:403-410, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the Internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx.
  • Stringent conditions are sequence- dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5° C to 20° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.
  • Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence remains hybridized to a perfectly matched probe or complementary strand.
  • nucleic acid molecules that hybridize under stringent conditions to a human polo-like kinase encoding sequence will typically hybridize to a probe based on either an entire human plk-1 encoding sequence or selected portions of the encoding sequence under wash conditions of 2 x SSC at 50° C.
  • nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences, due to the degeneracy of the genetic code. It is understood that changes in nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid molecules that all encode substantially the same protein.
  • Specific binding agent An agent that binds substantially only to a defined target.
  • a polo kinase (e.g., Plk) protein-specific binding agent binds substantially only the polo kinase protein.
  • the term "polo kinase specific binding agent” includes anti-polo kinase antibodies (and functional fragments thereof) and other agents (such as soluble receptors) that bind substantially only to a polo kinase protein. For instance, a Plk -specific binding agent would bind substantially only to Plk.
  • Anti-polo kinase antibodies may be produced using standard procedures described in a number of texts, including Harlow and Lane (Antibodies, A Laboratory Manual, CSHL, New York, 1988). The * determination that a particular agent binds substantially only to the selected polo kinase may readily be made by using or adapting routine procedures.
  • One suitable in vitro assay makes use of the Western blotting procedure (described in many standard texts, including Harlow and Lane (Antibodies, A Laboratory Manual, CSHL, New York, 1988)).
  • Western blotting may be used to determine that a given polo kinase binding agent, such as an anti- Plk protein monoclonal antibody, binds substantially only to the chosen polo kinase (e.g., Plk).
  • a given polo kinase binding agent such as an anti- Plk protein monoclonal antibody
  • Plk polo kinase binding agent
  • a specific method for the production of polyclonal anti- Plk antibodies can be found in Lee et al. (Mol. Cell Biol. 15:71433-7151, 1995), incorporated herein by reference.
  • Shorter fragments of antibodies can also serve as specific binding agents.
  • FAbs, * Fvs, and single-chain Fvs (SCFvs) that bind to Plk would be Plk -specific binding agents.
  • These antibody fragments are defined as follows: (1) Fab, the fragment which contains a monovalent antigen- binding fragment of an antibody molecule produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab', the fragment of an antibody molecule obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab')2, the fragment of the antibody obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; (4) F(ab')2, a dimer of two Fab' fragments held together by two disulfide bonds; (5) Fv, a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain
  • Target sequence is a portion of ssDNA, dsDNA or RNA that, upon hybridization to a therapeutically effective oligonucleotide or oligonucleotide analog, results in the inhibition of expression of a polo kinase, e.g., Plk or an ortholog thereof.
  • a polo kinase e.g., Plk or an ortholog thereof.
  • an antisense or a sense molecule can be used to target a portion of dsDNA, since both will interfere with the expression of that portion of the dsDNA.
  • the antisense molecule can bind to the plus strand, and the sense molecule can bind to the minus strand.
  • target sequences can be ssDNA, dsDNA, and RNA.
  • Therapeutically effective amount of (a substance) A quantity of a compound with pololike kinase modulating activity, a polo-box or related peptide, or a polo-box binding peptide sufficient to achieve a desired effect in a subject being treated. For instance, this can be the amount necessary to inhibit cellular proliferation or to measurably inhibit (or enhance) a polo-like kinase phosphorylating activity. For those embodiments in which the compound or peptide is used to inhibit cell proliferation, in general, a therapeutically effective amount will be sufficient to measurably inhibit proliferation of a target cell. Techniques for measuring such activity are discussed herein.
  • an effective amount of kinase modulating compound, polo box (or related peptide), or binding peptide may be administered in a single dose, or in several doses, for example daily, during a course, of treatment.
  • the effective amount of a composition will be dependent on the compound or peptide applied, the subject being treated, the severity and type of the affliction, and the , manner of administration of the composition.
  • a therapeutically effective amount of composition can vary from about 0.01 mg/kg body weight to about 1 g/kg body weight.
  • the therapeutic substances (compounds and peptides) disclosed have equal application in medical and veterinary settings. Therefore, the general term "subject being treated” is understood to include all animals (e.g. humans, apes, dogs, cats, horses, and cows) that are or may suffer from a cellular proliferation-related disease, disorder or condition that is susceptible to polo-like kinase pathway-mediated modulation.
  • a transformed cell is a cell into which has been introduced a nucleic acid molecule by molecular biology techniques.
  • transformation encompasses all techniques by which a nucleic acid molecule might be introduced into such a cell, including transfection with viral vectors, transformation with plasmid vectors, and introduction of naked DNA by electroporation, lipofection, and particle gun acceleration.
  • Tumor A neoplasm that may be either malignant or non-malignant.
  • Tumors of the same tissue type refers to primary tumors originating in a particular organ (such as breast, prostate, bladder or lung). Tumors of the same tissue type may be divided into tumor of different sub-types (a classic example being bronchogenic carcinomas (lung tumors) which can be an adenocarcinoma, small cell, squamous cell, or large cell tumor).
  • Variant polo-box related peptides Polo-box related peptides having one or more amino acid substitutions, one or more amino acid deletions, and/or one or more amino acid insertions, so long as the peptide retains the property of binding to a polo-box and thereby modulating a polo-box kinase function.
  • Conservative amino acid substitutions may be made in at least 1 position, for example 2, 3, 4, 5 or even 10 positions, as long as the peptide retains modulatory activity, as readily measured by the cytokinesis defect, yeast-based assay disclosed in the present specification.
  • Vector A nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
  • a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector may also include one or more selectable marker genes and other genetic elements known in the art.
  • cdc5 ⁇ N Cells expressing cdc5 ⁇ N appear to proceed through the cell cycle normally as evidenced by cycling Cdc28/Clb2 activity, which indicates that an intact polo-box is critical for selective inhibition of cytokinesis without disrupting mitotic exit.
  • Polo-box-dependent localization of Cdc5 at cytokinetic neck-filaments likely provides the temporal and spatial regulation of Cdc5, which may be important in coordinating the completion of mitosis with the initiation of cytokinesis.
  • Cdc5 carries out two important functions. First, in a polo-box-independent manner, Cdc5 activates APC, which leads to inactivation of Cdc28/Clb2, thereby permitting mitotic exit (left-hand pathway). Second, in a polo-box-dependent manner, Cdc5 localizes at cytokinetic neck-filaments and promotes the cytokinetic functions of septins (right-hand pathway).
  • Plasmid Construction All plasmids (Table 1, part 2) and yeast strains (Table 1, part 1) used in this study are listed below.
  • a PCR-amplified cdc5-l allele from strain KKY921-2BY was digested with PpuMl and BstE l to generate pSK877 (Song et al, Mol. Cell. Biol. 20:286-298, 2000).
  • a Plk-expressing integration construct was generated by inserting a SpeX-Sphl fragment of GAL 1-HA-EGFP-Plk from YCplacl 1 X-GALl-HA-EGFP-Plk (Lee et al, Proc. Natl. Acad. Sci. USA. 95:9301-9306, 1998) into a pUC19-77?P7 vector to yield pSK1267.
  • TUB1, CYK2, MYOl, or CDC3 constructs were integrated into the genome.
  • KpnX-NotX fragments containing either TUB1-GFP (from pAFS125; provided by Aaron F. Straight, Harvard Medical School, Boston, MA) or CYK2-GFP (from pLP2; provided by Rong Li, Harvard Medical School, Boston, MA) were inserted into YCplacl 11 vector digested with BglXX and Kpnl to generate pUC19- TUB1-GFP::LEU2 (pSK1050) and pVC ⁇ 9-CYK2-GFP::LEU2 (pSK1051).
  • pUC19-MTO7 ⁇ GFP::LEU2 (pSK1052) was generated by inserting a PstX-Notl fragment of MYOl-GFP (from pLP8; a gift of Rong Li) into the Pstl-Bglll fragment of YCplac 111 lacking both ARS and CEN loci.
  • p C19-YFP-CDC3::LEU2 was created by inserting the Sstl-Sphl fragment of CDC3 tagged N-terminally with YFP (a yellow-green variant of GFP; Clontech, Palo Alto, CA) into a pUC19-Z,£-/2 construct.
  • Gene disruption constructs for CYK2 (pSK1330), CDC 10 (pSK1332), and MYOl (pSK1348) were generated by inserting a 1.5 kb Bgl ⁇ X-Pmel fragment of KanMX ⁇ from pFA6a- ⁇ 3Myc-KanMX6 (Longtine et al, Yeast. 14:953-961, 1998) into the open reading frame of the corresponding genes in pLPl (CF-O-Myc, a gift of Rong Li), pSK1060 (YFP-CDC70), or pSK1052 (MYOl-GFP), respectively.
  • Strain KLY1229 was generated by integrating two additional copies of GAL1-HA- 2X(EGFP)-cdc5 ⁇ N/FAA::TRPl (pSK929) into strain KLY1081.
  • pSK929 To generate a swelA strain (KLY1439), a 2.3 kb Xbal fragment from pSWEl-XOg (Booher et al, EMBO J. 12:3417-3426, 1993) was transformed into strain KLY1083.
  • a 2 kb BainWl fragment from pSK1330 that contains the KanMX ⁇ and flanking CYK2 sequences was transformed into strain KLY1083.
  • MATa cells were arrested with 5 ⁇ g/ml ⁇ -factor mating pheromone (Sigma, St. Louis, MO). Treatment of the connected cells with zymolyase was performed as described previously (Frazier et ⁇ l, J. Cell Biol. 143:737-749, 1998; Lippincott and Li, J. Cell Biol. 140:355-366, 1998). Loss of the refractile appearance (indicating that cell wall removal was efficient under these conditions) was evident under the microscope.
  • Cell lysates were prepared in TED buffer (40 mM Tris-Cl (pH 7.5), 0.25 mM EDTA, 1 mM DTT, 1 mM AEBSF (Pefabloc; Boehringer Mannheim, IN), 10 ⁇ M/ml pepstatin A, 10 ⁇ M/ml leupeptin, and 10 ⁇ M/ml aprotinin) with an equal volume of glass beads (Sigma, St. Louis, MO).
  • TED buffer 40 mM Tris-Cl (pH 7.5), 0.25 mM EDTA, 1 mM DTT, 1 mM AEBSF (Pefabloc; Boehringer Mannheim, IN), 10 ⁇ M/ml pepstatin A, 10 ⁇ M/ml leupeptin, and 10 ⁇ M/ml aprotinin
  • Indirect immunofluorescence was performed as described previously (Lee et al, Proc. Natl. Acad. Sci. USA. 95:9301-9306, 1998). Briefly, cells cultured under induction conditions for the indicated time were fixed with 3.7% formaldehyde. Actin was localized using rhodamine-conjugated phalloidin (Molecular Probe, Eugene, OR). DNA was visualized with a 4',6-diamidino-2- phenylindole (DAPI). Confocal fluorescent images were collected with a Bio-Rad MRC 1024 confocal scan head mounted on a Nikon Optiphot microscope with a 60X planapochromat lens or with a Leica TCS spectrophotometer confocal microscope.
  • cdc5A strains were generated which were kept viable by expressing either its murine functional homolog Plk (KLY 1046) or the less-stable temperature sensitive mutant cdc5-l -encoded protein (Cheng et al, Mol. Cell. Biol. 18:7360-7370, 1998) (KLY1047), under control of the GALl promoter.
  • These strains possess an integrated copy of a green fluorescent protein (GFP)-fused TUB1 (TUB 1 -GFP) under control of its own promoter, to facilitate examination of dynamic spindle structures in mitosis.
  • GFP green fluorescent protein
  • TUB1 TUB1
  • strain KLY1046 was depleted of Plk for ten hours, whereas KLY1047 cells were depleted of cdc5-l protein for four hours. Cells arrested at different phases of the cell cycle were scored based on the spindle morphologies. Numbers shown are the average of two independent experiments. About 65% of strain KLY1046 (GALl -PLK) arrested at early anaphase with a short spindle elongated to, or extended just beyond, the mother-bud neck, whereas 25% of the population were arrested at cytokinesis with disassembled spindles (Table 2).
  • TUB1-GFP, CDC3-YFP, CYK2-GFP, and MYOl-GFP constructs were integrated into the cdc5-l mutant strain to compare the cdc5A phenotype with that of the cdc5-l mutation.
  • KLY1253 TUB1-GFP
  • KLY1260 YFP-CDC3
  • KLY1256 CYK2-GFP
  • KLY1258 MYOl-GFP
  • Cdc3 was present as double rings at the mother-bud neck, prior to relocalization to the future budding sites.
  • the Cyk2 ring was never seen as a single ring in these cells and the Myol ring appears to maintain normal size prior to contraction. Since the Cyk2 double ring merges to a single ring after the completion of spindle elongation and the contraction of the Cyk2 ring follows during spindle breakdown (Lippincott and Li, J. Cell Biol. 143:1947-1960, 1998), these cells arrested at a point prior to contraction. This is approximately 10-15 minutes into the cell cycle, between double Cyk2 ring stage with incompletely elongated spindle and initiation of contraction (see Lippincott and Li, J.
  • the non-catalytic C-terminal domain of Cdc5, which contains the polo-box, is sufficient to localize a protein at both the mother-bud neck and spindle poles, whereas introduction of a triple W517F V518A/L530A mutation (referred to hereafter as FAA) in the polo-box abolishes localization (Song et al, Mol. Cell. Biol. 20:286-298, 2000).
  • FAA triple W517F V518A/L530A mutation
  • over-expression of Cdc5, but not the FAA polo-box mutant can induce ectopic septin ring structures in abnormally elongated buds (Song et al, Mol. Cell. Biol. 20:286-298, 2000). Therefore, the polo-box is critical in the localization and cytokinetic function of Cdc5.
  • GAL1-EGFP GAL1-EGFP
  • GAL l-EGFP-cdc5 AN KLY 1082
  • GAL1-EGFP- cdc5AN/FAA KLY1081
  • mice expressing cdc5AN yield two fluorescent bands at the mother-bud neck and fluorescent dots in the cytoplasm, whereas the EGFP control and the corresponding FAA mutant show only diffuse signals.
  • the apparent multiple dot signals in strain KLY 1082 may be attributable to the ability of cdc5 ⁇ N to induce multiple subcellular structures containing Spc42, a component of spindle pole bodies (Song et al, Mol. Cell. Biol. 20:286-298, 2000).
  • strains KLY1082 and KLY1083 (expressing three copies of EGFP-cdc5AN; described below) do not possess any detectable growth defect in the presence of the anti-microtubule drug benomyl; these strains grow without a significant defect in the spindle checkpoint pathway.
  • Both EGFP-cdc5AN and EGFP-cdc5AN/FAA were expressed at similar levels, indicating that the observed phenotype associated with EGFP-cdc5AN expression was not due to a difference in protein abundance (FIG 2).
  • the observed chained cell phenotype indicates that overexpression of the cdc5 kinase-activity-deficient C-terminal domain (cdc5AN) may have resulted in a dominant- negative inhibition of a cytokinetic event normally regulated by endogeneous Cdc5.
  • endogeneous CDC5 was expressed in a low copy centromeric plasmid to determine if this could alleviate the chained cell growth pattern.
  • Cells expressing EGFP-cdc5AN under the control of GALl promoter (KLY1082) were transformed with wild type and various mutant forms of Cdc5.
  • Strain KLY 1083 was cultured under induction conditions in YEP-galactose; control strains expressing either EGFP alone (KLY1080) or an equal dosage of EGFP-cdc5AN/FAA (KLY1229) were grown under the same conditions.
  • KLY1083 cells When induced, KLY1083 cells yielded a connected cell phenotype in a time-dependent manner, whereas cells expressing the corresponding FAA mutant (KLY 1229) appear to divide normally with wild-type morphology. Upon inducing for nine hours, 98% of the population exhibited this phenotype, and 30% of them possess more than ten connected cell bodies. In contrast, cells expressing the FAA mutant did not show this morphology (Table 4). This table shows the time- dependent accumulation of chained cells, and length of cell chains. Percentage of cells in chains was determined by dividing the sum of cells in chains by the total number of cells. Table 4
  • the extent to which the chained cells maintained cytoplasmic connections was examined.
  • KLY1083 cells cultured under induction conditions for 12 hours were treated with zymolyase to remove the cell wall, and the cell (spheroplast) number was counted. Even after extensive zymolyase treatment, cells largely remained as clumps of unseparated cells without a significant increase in the number of individual cells.
  • the connected cell phenotype therefore, is the result of a cytokinetic defect as defined by the criteria described previously (Hartwell, Exp. Cell Res. 69:265-276, 1971).
  • strain KLY1083 expressing EGFP-cdc5AN failed to regenerate a distinct IC (Gl) peak, and continued to accumulate DNA to greater than 2C (G2/M) peak. Accumulation of cells with higher DNA contents appears to be the result of induction of connected cells.
  • cellular lysates from cells used in the flow cytometry experiment were subjected to Western blot analyses to examine changes in Clb2 and EGFP-cdc5 ⁇ N levels upon release from a ⁇ -factor arrest.
  • the level of Cdc28 was determined as a loading control for each lane.
  • the same lysates were also used to carry out anti-Clb2 immune complex kinase assays to measure the Clb2-associated histone HI kinase activities.
  • Control strain KLY 1080 achieved the maximum Cdc28/Clb2 activity (onset of M phase) at 60 minutes and 150 minutes after release from cell cycle arrest. (Samples beyond 240 minutes after release were not taken because of lack of cell cycle synchrony.
  • Strain KLY1229 (cdc5 ⁇ N/FAA) exhibited a slight delay in the cell cycle in comparison to the EGFP control strain, whereas strain KLY1083 (cdc5 ⁇ N) had a 20 minute delay.
  • Clb2 protein levels and Clb2-associated kinase activities appeared to fluctuate normally and with similar kinetics, hence overexpression of cdc5 AN did not efficiently prevent endogeneous Cdc5 from activating APC.
  • approximately equal amounts of EGFP control, EGFP-cdc5 ⁇ N, and EGFP-cdc5 ⁇ N/FAA proteins were expressed in these cells.
  • Cdc28/Clb2 activity appeared to fluctuate normally in strain KLY1083, which overexpresses EGFP-cdc5AN.
  • overexpression of EGFP-cdc5 ⁇ N appears to selectively inhibit cytokinesis without significantly perturbing the nuclear division cycle during the early stage of connected cells.
  • the chained (connected) cell phenotype could be achieved by continuous division of peripheral cells in the absence of cytokinesis.
  • KLY 1069 To examine the cell cycle stage of individual cell bodies in the connected cells, a new strain (KLY 1069) was created. To make this strain, a copy of a TUB 1 -GFP fusion was integrated into the genome of KLY 1053 (expressing a GST-fused cdc5 ⁇ N (GST-cdc5AN) under control of the GALl). Strain KLY1069 grew normally and exhibited normal spindle structures in YEP-glucose.
  • strain KLY1053 was additionally integrated with CDC3-YFP (KLY1075), CYK2-GFP (KLY1071), or MYOl-GFP (KLY1073) under control of their own promoters. These strains grew normally with apparently normal ring structures when cultured in YEP-glucose. Upon induction of GST-cdc5 ⁇ N, cells were examined to determine whether these components formed normal ring structures.
  • septin rings appear to be assembled normally at the growing edge of the connected cells, thereby permitting normal budding events. These ring structures are cytokinesis-incompetent, resulting in the generation of the connected cell morphology. As with septin ring structures persisting at most of the mother-bud necks of connected cells, both Cyk2-GFP and Myol -GFP ring structures were also remained at these sites. This observation further supports the notion that cytokinetic processes have failed in these cells.
  • a yeast two-hybrid system was used to investigate whether Cdc5 directly interacts with septins.
  • a destruction-box deficient form of Cdc5 (Song et al, Mol. Cell. Biol. 20:286-298, 2000) was used in place of the wild-type protein to increase protein stability for these experiments.
  • septin ring structures are largely disturbed in the connected (chained) cells, the presence of contraction-size Cyk2 or Myol rings suggests that overexpression of cdc5AN did not completely eliminate the function of septin rings in these cells.
  • the two cytokinetically important * components, Myol and Cyk2 function in parallel pathways and localize at neck-filaments in a septin-dependent manner. Since overexpression of cdcSAN partially inhibits septin function, introduction of either a cyk2A or a myol A mutation into the connected cells may enhance the severity of the chained cell phenotype.
  • Strain KLY1083 was modified with the additional of a cyk2A (KLY1591), myol A (KLY1593), or cdclOA (KLY1589) mutation, and examined under induction conditions (streaked onto YEP-galactose and, for comparison, YEP-glucose).
  • cyk2A KLY1591
  • myol A KLY1593
  • cdclOA KLY1589
  • both KLY 1591 and KLY 1593 cells displayed a significantly enhanced connected cell morphology, in comparison to those of the corresponding cyk2A or myol A single mutants or cells overexpressing cdc5AN alone.
  • the observed synthetic growth defect is the result of the synthetic cytokinetic defect and indicates that the cytokinetic pathways regulated by Cyk2 and Myol are mediated by septins.
  • cdc5AN Over-expression of cdc5AN, but not the corresponding polo-box mutant, results in dominant-negative inhibition of cytokinesis without interfering with mitotic exit. This over- expression disturbs septin ring structures, likely through interaction of Cdc5 with two septins, Cdcl 1 and Cdcl2. These interactions occur in a polo-box-dependent manner in a yeast two-hybrid system. Thus, overexpression of cdc5AN may prevent endogeneous Cdc5 from interacting with septins and carrying out its cytokinetic function.
  • the septins are thought to be the major structural components of the neck filaments (Frazier et al, J. Cell Biol. 143:737-749, 1998). Interactions between Cdc5 and septins suggest that localization of EGFP-cdc5 ⁇ N at the mother-bud neck may require septins and higher-order cytokinetic neck-filaments. Since a cdclOA mutant grows normally at 23° C, but does not possess detectable neck-filaments (Frazier et al, J. Cell Biol. 143:737-749, 1998), a cdclOA mutation was introduced into KLY1083 strain (KLY1589).
  • Cdc5 activity may not be required for initiation of septin ring formation, since Cdc5 is expressed in a late phase of the cell cycle and its kinase activity peaks in mitosis.
  • septin ring structures are weakened but not completely disassembled in a cdc5-l mutant at the restrictive temperature (Kim et al, J. Cell Biol. 112:535-544, 1991).
  • Cdc5 activity may not be important for the assembly of septin rings into a higher-order structure, but rather it may be important for maintaining or reinforcing a cytokinetically competent structure. Data reported here indicate that septin rings at the edge cells of cell chains appear to be relatively normal, as evidenced by continuous budding events.
  • septins form a ring at the neck of growing buds, but fail to maintain a cytokinesis-competent structure. Since remnants of septin materials are found between mother-bud necks without proper relocalization to the future budding sites, overexpression of cdcSAN may also disturb one or more steps that are important for disassembly of septin ring structures.
  • cdc5 ⁇ N protein Overexpression of the dominant-negative cdc5 ⁇ N protein appears to induce a partial inhibition of cytokinesis as demonstrated by the presence of Cyk2 and Myol rings the size of contractile ring, and occasional membrane closures between budding cells. Since both Myol and Cyk2 localization is depend on septin ring structures, it is likely that septins play a central role in regulating both cytokinetic pathways. Introduction of either myol A or cyk2A into the strain overexpressing cdcSAN enhances the cytokinetic defects.
  • septin-defective cells lose viability, likely because septins play additional roles in other stages of the cell cycle.
  • cells overexpressing cdcSAN exhibit round cell bodies that are connected (chained), and which form colonies on YEP-glucose medium. These cells go through the cell cycle essentially normally, with cycling Cdc28/Clb2 activity. In the absence of complete cell division, these cultures continue to increase cell mass (though not individualized cell number) by continuous budding events at the periphery of the chained cells.
  • septins have been shown to cause defects in bud site selection.
  • the chained cells observed with strain KLY1083 (an a-type haploid) exhibited a largely unipolar budding pattern, whereas these cells develop a new bud at the proximal pole of previous cytokinetic site when grown in YEP-glucose medium.
  • These observations indicate that, in the absence of cytokinesis, the distal pole of the daughter cell is favored for subsequent budding event.
  • changes in budding pattern may be attributable to the absence of proper septin relocalization to the future budding sites in the internal cell bodies, while maintaining polar budding at the peripheral cells.
  • the disturbance in septin ring structures in the connected cells results in a cytokinetic defect that is accompanied by a budding defect.
  • Cdc5 plays dual roles in a late stage of M phase.
  • Cdc5 activity is required for proper function of septin ring structures required for cytokinesis.
  • a fraction of Cdc5 relocalizes to the bud-neck to carry out its cytokinetic function(s), a relocalization event that requires an intact polo-box.
  • a dominant-negative cdc5 ⁇ N which localizes at the neck-filament, does not interfere with APC activation or the mitotic exit pathway.
  • Cdc5/Plk activity may have induced abnormally elongated buds by activation of APC, whereas ectopic septin rings may have arisen by reinforcing septin ring organization.
  • Activation of the APC apparently does not require polo-box-dependent localization of Cdc5 at the septin rings, whereas overexpression of the polo-box domain is sufficient to inhibit cytokinesis.
  • temporal and spatial regulation of Cdc5 provides an important mechanism to coordinate mitotic exit pathway with initiation of cytokinesis.
  • Deletion constructs shown in FIG 9A, were constructed using standard molecular biology techniques to examine importance of the polo boxes of Plk in mammalian cells.
  • Constructs #1 and #3 are different deletions of Plk, missing the sequence encoding the kinase domain (contained on the Xhol to BamHI fragment or the Nael to Smal fragment, respectively).
  • Constructs #2 and #4 are polo-box deletion variants of #1 and #3, respectively, wherein polo-boxes 2 and 3 have been removed by deletion of the Sstl to Sstl fragment.
  • Recombinant HA-GFP-Plk was generated by N-terminally tagging Plk with HA (hemagglutinin epitope) and GFP (green fluorescence protein).
  • Adenoviral expression constructs bearing various forms of HA-GFP-PLK cDNA were expressed in HEK293 cells using the pAdEasy-1 expression system (He, Proc. Natl. Acad. Sci., USA, 1998. 95:2509-2514). Expression of these proteins was detected with anti-HA antibody using enhanced chemoluminiscence Western analysis (FIG 9B).
  • constructs #1 - #4 induce a prometaphase arrest in HeLa cells, as judged by immunostaining with an anti-tubulin antibody and an anti-centrosome antibody.
  • flow cytometry analyses with the cells infected with these viruses show a mitotic arrest, which is accompanied by cell death.
  • Polo-box 2 and 3 of Plk are required to localize at midbody in HeLa cells.
  • Polo-box 1 of Plk is sufficient to localize at centrosomes in HeLa cells.
  • adenoviral constructs expressing various deletion variants of recombinant HA-GFP-Plk were infected into HeLa cells. Centrosomes were visualized by staining the cells with an anti-alpha tubulin antibody, whereas Plk localization was detected as GFP signals. All four deletion constructs were able to localize at centrosomes.
  • a recombinant protein e.g., a polo-box-related peptide as described herein
  • an expression vector carrying the nucleic acid sequence that encodes the desired protein will be transformed into a microorganism for expression.
  • microorganisms can be prokaryotic (bacteria) or eukaryotic (e.g., yeast).
  • bacteria prokaryotic
  • eukaryotic e.g., yeast
  • E. coli Escherichia coli
  • An eukaryotic expression system can be used where the protein of interest requires eukaryote-specific post-translational modifications such as glycosylation.
  • protein can be expressed using a viral (e.g., vaccinia) based expression system.
  • Protein can also be expressed in animal cell tissue culture, and such a system can be used where animal-specific protein modifications are desirable or required in the recombinant protein.
  • Vectors suitable for stable transformation of culturable cells are also well known.
  • such vectors include a multiple-cloning site suitable for inserting a cloned nucleic acid molecule, such that it will be under the transcriptional control of 5' and 3' regulatory sequences.
  • transformation vectors include one or more selectable markers; for bacterial transformation this is often an antibiotic resistance gene.
  • Such transformation vectors typically also contain a promoter regulatory region (e.g, a regulatory region controlling inducible or constitutive expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, and a transcription termination site, each functionally arranged in relation to the multiple-cloning site.
  • an inducible promoter can be used for production of large amounts of recombinant proteins. This permits selective production of the recombinant protein, and allows both higher levels of production than constitutive promoters, and enables the production of recombinant proteins that may be toxic to the expressing cell if expressed constitutively.
  • protein expression/purification kits are produced commercially. See, for instance, the QIAexpressTM expression system from QIAGEN (Chatsworth, CA) and various expression systems provided by INVITROGEN (Carlsbad, CA). Depending on the details provided by the manufactures, such kits can be used for production and purification of the disclosed polo-box related peptides.
  • purification affinity-tags for instance a six-histidine sequence, may be recombinantly fused to the protein and used to facilitate polypeptide purification.
  • a specific proteolytic site for instance a thrombin- specific digestion site, can be engineered into the protein between the tag and the fusion itself to facilitate removal of the tag after purification.
  • Protein expression/purification kits provide tailored protocols for the purification of proteins made using each system. See, for instance, the QIAexpressTM expression system from QIAGEN (Chatsworth, CA) and various expression systems provided by INVITROGEN (Carlsbad, CA). Where a commercial kit is employed to produce a protein, the manufacturer's purification protocol is a particularly disclosed protocol for purification of that protein. For instance, proteins expressed with an amino-terminal hexa-his tag can be purified by binding to nickel-nitrilotriacetic acid (Ni-NTA) metal affinity chromatography matrix (The QIAexpressionist, QIAGEN, 1997).
  • Ni-NTA nickel-nitrilotriacetic acid
  • the polo-box related peptide is produced in a secreted form, e.g. secreted into the milk of a transgenic animal, purification will be from the secreted fluid. Alternately, purification may be unnecessary if the peptide can be applied directly to the subject in the secreted fluid (e.g. milk).
  • secreted fluid e.g. milk
  • the binding characteristics, and therefore polo-like kinase function modulatory activity, of the polo-box peptides disclosed herein lie not in the precise amino acid sequence, but rather in the three-dimensional structure inherent in the amino acid sequences encoded by the DNA sequences. It is possible to recreate the binding characteristics of any of these peptides, proteins or protein domains of this disclosure by recreating the three-dimensional structure, without necessarily recreating the exact amino acid sequence. This can be achieved by designing a nucleic acid sequence that encodes for the three-dimensional structure, but which differs, for instance by reason of the redundancy of the genetic code. Similarly, the DNA sequence may also be varied, while still producing a functional binding peptide.
  • Variant polo-box related peptides include those that differ in amino acid sequence from the disclosed sequence (SEQ ID NO: 1), but that share structurally significant sequence homology with any of the provided proteins.
  • SEQ ID NO: 1 amino acid sequence from the disclosed sequence
  • Table 5 Original Residue Conservative Substitutions
  • More substantial changes in protein structure may be obtained by selecting amino acid substitutions that are less conservative than those listed in Table 5. Such changes include changing residues that differ more significantly in their effect on maintaining polypeptide backbone structure (e.g., sheet or helical conformation) near the substitution, charge or hydrophobicity of the molecule at the target site, or bulk of a specific side chain.
  • polypeptide backbone structure e.g., sheet or helical conformation
  • substitutions are generally expected to produce the greatest changes in protein properties: (a) a hydrophilic residue (e.g., seryl or threonyl) is substituted for (or by) a hydro phobic residue (e.g., leucyl, isoleucyl, phenylalanyl, valyl or alanyl); (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain (e.g., lysyl, arginyl, or histadyl) is substituted for (or by) an electronegative residue (e.g., glutamyl or aspartyl); or (d) a residue having a bulky side chain (e.g., phenylalanine) is substituted for (or by) one lacking a side chain (e.g., glycine).
  • a hydrophilic residue e.g., seryl or threonyl
  • Variant binding peptides or peptide-encoding sequences may be produced by standard DNA mutagenesis techniques, for example, M13 primer mutagenesis. Details of these techniques are provided in Sambrook (In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989), Ch. 15. By the use of such techniques, variants may be created which differ in minor ways from the polo-box peptide-encoding sequences disclosed.
  • Peptide sequences which are derivatives of those specifically disclosed herein and that differ from those disclosed by the deletion, addition, or substitution of amino acids while still encoding a peptide or protein that competes with a native polo-box for binding to a specific site, thereby modulating a polo-like kinase function in a cell or cell-free system, are comprehended by this disclosure.
  • the coding region may be altered by taking advantage of the degeneracy of the genetic code to alter the coding sequence such that, while the nucleotide sequence is substantially altered, it nevertheless encodes a protein having an amino acid sequence substantially similar to the disclosed fusion sequences.
  • variant DNA molecules may be derived from encoding sequences disclosed herein using standard DNA mutagenesis techniques as described above, or by synthesis of DNA sequences.
  • this disclosure also encompasses nucleic acid sequences which encode a polo-box related peptide, but which vary from the disclosed sequences by virtue of the degeneracy of the genetic code.
  • the present disclosure includes biologically active molecules that mimic the action of the polo-box peptides and polo-box related peptides of the present disclosure, and specifically compete with a polo- like kinase for binding at a specific cellular site.
  • the proteins and peptides of the disclosure include synthetic embodiments of naturally-occurring proteins described herein, as well as analogues (non-peptide organic molecules), derivatives (chemically functionalized protein molecules obtained starting with the disclosed peptide sequences) and variants (homologs) of these proteins that specifically compete with native polo-like kinase for binding, e.g. binding to an element of the neck filaments or other cytokinetic structure.
  • Each protein or peptide is comprised of a sequence of amino acids, which may be either L- and/or D- amino acids, naturally occurring and otherwise.
  • Proteins and peptides may be modified by a variety of chemical techniques to produce derivatives having essentially the same activity as the unmodified proteins, and optionally having other desirable properties.
  • carboxylic acid groups of the protein may be provided in the form of a salt of a pharmaceutically-acceptable cation or esterified to form a C,-C 16 ester, or converted to an amide of formula NR,R 2 wherein R, and R 2 are each independently H or C,-C 16 alkyl, or combined to form a heterocyclic ring, such as a 5- or 6- membered ring.
  • Amino groups of the protein may be in the form of a pharmaceutically-acceptable acid addition salt, such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts, or may be modified to C,-C 16 alkyl or dialkyl amino or further converted to an amide.
  • a pharmaceutically-acceptable acid addition salt such as the HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric and other organic salts
  • Hydroxyl groups of the protein side chains may be converted to C,-C 16 aikoxy or to a C,-C 16 ester using well-recognized techniques.
  • Phenyl and phenolic rings of the protein side chains may be substituted with one or more halogen atoms, such as fluorine, chlorine, bromine or iodine, or with C,- C 16 alkyl, C,-C 16 aikoxy, carboxylic acids and esters thereof, or amides of such carboxylic acids.
  • Methylene groups of the protein side chains can be extended to homologous C 2 -C 4 alkylenes.
  • Thiols can be protected with any one of a number of well-recognized protecting groups, such as acetamide groups.
  • Peptidomimetic and organomimetic embodiments are also within the scope of the present disclosure, whereby the three-dimensional arrangement of the chemical constituents of such peptido- * and organomimetics mimic the three-dimensional arrangement of the protein backbone and component amino acid side chains in the protein, resulting in such peptido- and organomimetics of the proteins of this disclosure having measurable or enhanced inhibiting or enhancing ability.
  • a pharmacophore is an idealized, three-dimensional definition of the structural requirements for biological activity.
  • Peptido- and organomimetics can be designed to fit each pharmacophore with current computer modeling software (using computer assisted drug design or CADD).
  • a polo-like kinase C-terminal region which includes a polo-box, or a derivative or variant of a polo-box
  • a polo-like kinase C-terminal region which includes a polo-box, or a derivative or variant of a polo-box
  • the reported constructs and strains include a 465 amino acid fragment of a polo-like kinase (corresponding to residues 240-705 of Cdc5), it is believed possible to use a shorter or longer fragment of the protein domain.
  • the core polo-box consensus sequence is found at residues 513 through 542 of Cdc5 or residues 410 through 439 of mammalian Plk.
  • other polo-box related peptides can include about residues 493 through 562 of Cdc5 (having about 20 additional residues on either side of the consensus box), or about residues 473 through 582 of Cdc5 (with about 40 additional residues on each side), or about residues 413 through 652 (with about 100 additional residues on each side).
  • polo-box related peptides can be readily assessed.
  • functional assays of peptide function permit optimization of the length of the peptide either chosen from the C-terminal domain of a polo-like kinase, or the design (including length) of a heterologous peptides containing a polo-box like sequence.
  • Polo-box related peptide activity is the ability of the peptide to bind to a polo-box specific interacting molecule, for instance a polo-box receptor. More specifically, interaction of the polo-box related peptide with a neck filament component (such as septins Cdc 11 and Cdc 12) or a spindle pole component (such as Bbpl) is measured to determine the activity of the peptide. Methods for examining such interactions include those disclosed herein, such as direct measurement of protein- peptide interactions, interaction in a yeast two hybrid system, or alteration/modification of a cytokinesis-related eukaryotic growth phenotype. Control molecules may be included in each assay. Usually at least one control peptide will include one or more point mutations within its conserved polo-box domain (see SEQ ID NO: 1). Specific examples of such mutations are described herein.
  • Example 4 Use of Eukaryotic Cells Overexpressing a Polo- box or Related Peptide to Isolate Compounds with Polo-like Kinase Modulating Activity
  • the eukaryotic cells disclosed herein which express or over-express a polo-box or related peptide, can be used to identify compounds that modify a polo-box-dependent function of a polo-like kinase.
  • these identified compounds will inhibit polo-like kinase function; in other embodiments, compounds are isolated that enhance (activate) polo-like kinase function.
  • Inhibitory compounds identified in this manner can be, for instance, used to inhibit or reduce cellular proliferation, such as proliferation caused by a hyper-proliferative disorder, disease or condition.
  • the cytokinesis-defective phenotype that is exploited for identification of kinase function modulatory compounds, as described herein, is recognizable but may be slightly different in different experimental organisms (e.g., yeast cultures versus animal cell lines). Stably expressing the C- terminal domain of Plk (plk ⁇ N) or Cdc5 (cdcSAN) induces chains of connected yeast cells. Specific examples of yeast strains that exhibit this cytokinetic-defective phenotype include the S. cerevisiae strains KLY1212 (which expresses EGFP-plkAN) and KLY1083 (which expresses EGFP-cdc5 ⁇ N).
  • Cells from non-yeast organisms can be similarly used to identify compounds that have pololike kinase modulating activity.
  • a C-terminal domain of a pololike kinase (or a derivative or fragment thereof that maintains polo-box activity) is heterologously expressed or over-expressed in cells of a eukaryotic organism.
  • the phenotype resulting from this heterologous expression is examined.
  • yeast particularly S. cerevisiae, as disclosed herein
  • such over expression causes a chaining/connected phenotype that is directly linked to polo-box dependent defects in cytokinesis.
  • spindle poles were also induced, likely through interaction with spindle pole component Bbpl.
  • mammalian cells in particular, the mouse-derived cell line SI
  • expression of two different plkAN constructs results in a mitotic arrest phenotype, in which the cultured cells round up on growth dishes.
  • Similar observations can readily be made with cells from other organisms, including other mammalian cell lines (e.g., human-derived cell lines), cells from C. elegans, fungi (including ⁇ S. pombe), etc.
  • yeast polo-like kinase Cdc5 can serve as a source of the polo-box used to generate a peptide that is over expressed in mammalian cells.
  • a mammalian polo-like kinase such as Plkl
  • Plkl a mammalian polo-like kinase
  • Eukaryotic cells expressing or over expressing a polo-box as described herein can be used for screening compounds for therapeutic activity (e.g., to identify compounds that modify cellular proliferation and/or cytokinesis), including compounds developed by combinatorial library technology.
  • Combinatorial library technology provides an efficient way of testing a vast number of different potentially therapeutic substances for an activity, e.g., the ability to inhibit binding of a polo-box (or related peptide) to a specific receptor/binding site. Construction of such combinatorial libraries and their use are known in the art (see, e.g., U.S. Patent Nos. 5,045,755, 5,565,324, 5,663,046, 5,723,598, and 6,061,636).
  • a method of screening for a compound that modulates a polo-like kinase function may include contacting one or more test compounds (e.g., from a combinatorial library) with cells of the yeast strain in a suitable reaction chamber (such as a microtiter plate well). The cells are then incubated for a time sufficient to permit an effect of the test compound to be felt by the cells, and the cells are then assessed for whether or not the compound affected any change to the cells. Such assessment can include, for instance, visual (e.g., microscopic) examination of the cells to determine if the proportion of cells exhibiting a cytokinesis-defective phenotype has changed.
  • such assessment can include determination of the subcellular localization of one or more proteins or peptides within the yeast cells.
  • the subcellular localization of a polo-like kinase or another cytokinesis-functional protein can be examined.
  • a difference in a polo-like kinase in the cell after exposure to a compound is indicative of the compound having polo-like kinase modulatory activity.
  • a compound with polo-box inhibitory activity may be identified as reducing an apparent cytokinesis-Zmitosis-defective phenotype in a eukaryotic cell expressing a heterologous polo-box related peptide; this same compound will exhibit cytokinesis-/mitosis -inhibitory (and/or other polo-like kinase function inhibitory) activity when applied to a cell that is not expressing the heterologous peptide.
  • a compound identified with the same identification assay as enhancing the cytokinesis-/mitosis -defective phenotype is a polo-box activating compound.
  • This class of compounds when applied to a cell that is not expressing a heterologous polo-box peptide, may cause an increase in apparent polo-box activity within the cell.
  • Such enhancing/activating compounds can, for instance, include compounds that stabilize the association between a polo-box (either in a peptide or heterologous protein, or in a native polo-like kinase) and a specific polo-box binding target (such as a component of the neck filaments or spindle poles). Since activation of polo kinases results in an increase in cytokinesis in budding yeast, it is likely that a specific polo-box enhancing compound can potentiate the ability of polo kinases to induce bud elongation and ectopic cytokinetic structures.
  • a compound identified by the herein-described methods as a modulator of polo-like kinase function may be of a peptide or non-peptide nature.
  • Non-peptide "small molecules" are preferred for some embodiments, such as certain in vivo pharmaceutical uses.
  • compositions that include, as an active ingredient, at least one kinase- activity modifying compound, polo-box binding peptide, or polo-box related peptide (as described herein) will normally be formulated with a solid or liquid carrier, depending upon the particular mode of administration chosen.
  • the pharmaceutically acceptable carriers and excipients useful in this disclosure are conventional.
  • parenteral formulations usually comprise injectable fluids that are pharmaceutically and physiologically acceptable fluid vehicles such as water, physiological saline, other balanced salt solutions, aqueous dextrose, glycerol or the like.
  • Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations.
  • the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • doxorubicin Other medicinal and pharmaceutical agents, for instance ifosamide, cisplatin, methotrexate, procarizine, etoposide, BCNU, vincristine, vinblastine, cyclophosphamide, gencitabine, 5- flurouracie, paclitaxel, or doxorubicin, also may be included. It may also be advantageous to include other known anti-cancer drugs.
  • the dosage form of the pharmaceutical composition will be determined by the mode of administration chosen.
  • topical and oral formulations can be employed.
  • Topical preparations can include eye drops, ointments, sprays and the like.
  • Oral formulations may be liquid (e.g., syrups, solutions or suspensions), or solid (e.g., powders, pills, tablets, or capsules).
  • solid compositions conventional non-toxic solid carriers can include pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art.
  • compositions that comprise a kinase-activity-modifying compound and/or a polo-box peptide and/or a polo-box binding peptide may be formulated in unit dosage form, suitable for individual administration of precise dosages.
  • One possible unit dosage contains approximately 100 ⁇ g of the compound or peptide.
  • the amount of active molecule (either a kinase- activity modifying compound, polo-box peptide, or polo-box binding peptide) administered will be dependent on the subject being treated, the severity of the affliction, and the manner of administration, and is best left to the judgment of the prescribing clinician. Within these bounds, the formulation to be administered will contain a quantity of the active component(s) in an amount effective to achieve the desired effect in the subject being treated.
  • the potent cytokinesis-modulatory (e.g., inhibitory) activity exhibited by the disclosed compounds and peptides makes them useful for treating proliferative disorders, diseases and conditions in human and other animal subjects.
  • Possibly susceptible diseases, disorders and conditions include neoplasms, and more specifically tumors of various origins (lung, colon, stomach, smooth muscle, esophagus, non-Hodgkin's lymphoma, non-small cell lung cancer, etc.).
  • Kinase- modulatory compounds and peptides disclosed herein can be used, for instance, to prevent or inhibit cellular proliferation or growth, for instance in a tumor, such as a malignant neoplasm.
  • the compounds and peptides of this disclosure may be administered to humans, or other animals on whose cells they are effective, in various manners such as topically, orally, intravenously, intramuscularly, intraperitoneally, intranasally, mtradermally, intrathecally, and subcutaneously.
  • the particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g., the subject, the disease, the disease state involved, and whether the treatment is prophylactic).
  • Treatment may involve daily or multi-daily doses of compound(s) and/or peptide(s) over a period of a few days to months, or even years.
  • such cells may be administered at a dose of between about 10 6 and 10 10 cells, on one or several occasions.
  • the number of cells will depend on the patient, as well as the binding peptide and cells chosen to express the protein.
  • a general strategy for transferring genes into donor cells is disclosed in U.S. Patent No. 5,529,774, which is incorporated by reference.
  • a gene encoding a protein or peptide having therapeutically desired effects is cloned into a viral expression vector, and that vector is then introduced into the target organism.
  • the virus infects the cells, and produces the protein sequence in vivo, where it has its desired therapeutic effect. See, for example, Zabner et al, Cell 75:207-216, 1993.
  • telomeres As an alternative to adding the sequences encoding a polo-box (or related peptide), binding peptide or a homologous protein to the DNA of a virus, it is also possible to introduce such a gene into the somatic DNA of infected or uninfected cells, by methods that are well known (Sambrook et al, In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York, 1989). These methods can be used to introduce nucleic acids encoding the herein-disclosed peptides into human cells to provide long-tenn inhibition of cellular proliferation. For example, gene therapy can be used to secrete the peptides in cells localized at or near a neoplasm.
  • the present disclosure also includes combinations of kinase-activity modifying compounds and/or polo-box related peptides with one or more other agents useful in the treatment of a disorder, condition, or disease, e.g. a hyper-proliferative disorder such as neoplasm.
  • the compounds and/or peptides of this disclosure may be administered in combination with effective doses of other anti-proliferatives, anti-cancer agents, immunomodulators, anti-inflammatories, anti- infectives, and/or vaccines.
  • administration in combination refers to both concurrent and sequential administration of the active agents.
  • anti-proliferatives examples include the following: ifosamide, cisplatin, methotrexate, procarizine, etoposide, BCNU, vincristine, vinblastine, cyclophosphamide, gencitabine, 5-flurouracie, paclitaxel, or doxorubicin.
  • immuno-modulators examples include AS-101 (Wyeth-Ayerst Labs.), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immune globulin (Cutter Biological), IMREG (from Imreg of New La, La.), SK&F106528, and TNF (Genentech).
  • the combination therapies are of course not limited to the lists provided in these examples, but includes any composition for the treatment of a hyper-proliferative disorder.
  • the kinase-activity modifying compounds and peptides disclosed herein can be supplied in the form of kits for use in prevention and/or treatment of a disorder, condition or diseases (e.g., a hyper-proliferative disorder, such as neoplasm).
  • a clinically effective amount of one or more of the compounds or peptides is provided in one or more containers.
  • the compounds or peptides may be provided suspended in an aqueous solution or as a freeze-dried or lyophilized powder, for instance.
  • the compounds or peptides will be provided in the form of a pharmaceutical composition.
  • Kits can also include instructions, usually written instructions, to assist the user in treating a disorder, condition or disease (e.g., a hyper-proliferative disorder, such as neoplasm) with a kinase- activity modifying compound and/or binding peptide.
  • a disorder, condition or disease e.g., a hyper-proliferative disorder, such as neoplasm
  • Such instructions can optionally be provided on a computer readable medium.
  • the container(s) in which the compound(s) and or peptide(s) are supplied can be any conventional container that is capable of holding the supplied form, for instance, microfuge tubes, ampoules, or bottles.
  • the therapeutic compound or peptide may be provided in pre-measured single use amounts in individual, typically disposable, tubes or equivalent containers.
  • the amount of a compound or peptide supplied in the kit can be any appropriate amount, depending for instance on the market to which the product is directed. For instance, if the kit is adapted for research or clinical use, the amount of each kinase-activity modifying compound or binding peptide provided would likely be an amount sufficient for several treatments.
  • kits will also include one or more other agents useful in inhibiting cell proliferation, e.g. in treating hyper-proliferation.
  • such kits may include one or more effective doses of other anti-proliferative or anti-cancer drugs.
  • a reduction of Polo-like kinase expression in a transgenic cell may be obtained by introducing (either transiently or permanently) into cells an antisense construct based on a Polo-like kinase encoding sequence.
  • an antisense construct based on a Polo-like kinase encoding sequence.
  • a complementary nucleotide sequence or the polo-like kinase transcript from the Polo-like kinase e.g. all or a portion of the kinase cDNA or gene, is expressed from the transformation vector.
  • Other aspects of the vector may be chosen as discussed above (Example 1).
  • the introduced sequence need not be a full length Polo-like kinase cDNA or gene, and need not be exactly homologous to the equivalent sequence found in the cell type to be transformed. Generally, however, where the introduced sequence is of shorter length, a higher degree of homology to the complementary sequence of the native Polo-like kinase transcript sequence will be needed for effective antisense suppression.
  • the introduced antisense sequence in the vector may be at least 30 nucleotides in length, and improved antisense suppression will typically be observed as the length of the antisense sequence increases.
  • the length of the antisense sequence in the vector advantageously may be greater than 100 nucleotides. For suppression of a Polo- like kinase gene itself, transcription of an antisense construct results in the production of RNA molecules that are the reverse complement of mRNA molecules transcribed from the endogenous Polo-like kinase gene in the cell.
  • antisense RNA molecules bind to the endogenous mRNA molecules and thereby inhibit translation of the endogenous mRNA.
  • Ribozymes are synthetic RNA molecules that possess highly specific endoribonuclease activity. The production and use of ribozymes are disclosed in U.S. Patent No. 4,987,071 to Cecil and U.S. Patent No. 5,543,508 to Haselhoff. The inclusion of ribozyme sequences within antisense RNAs may be used to confer RNA cleaving activity on the antisense RNA, such that endogenous mRNA molecules that bind to the antisense RNA are cleaved, which in turn leads to an enhanced antisense inhibition of endogenous gene expression.
  • Polo-like kinase expression can be, for instance, used to treat cellular proliferative and other disorders, in particular hyper-proliferative disorders such as neoplasm.
  • Retroviruses have been considered a preferred vector for experiments in gene therapy, with a high efficiency of infection and stable integration and expression (Orkin et al, Prog. Med. Genet. 7:130-142, 1988).
  • a full-length Polo-like kinase gene or cDNA can be cloned into a retroviral vector and driven from either its endogenous promoter or from the retroviral LTR (long te ⁇ ninal repeat).
  • a shorter portion of a Polo-like kinase encoding sequence (encoding only the polo-box, or this consensus box and some amount of flanking region) can be cloned into the retroviral vector.
  • Other viral transfection systems may also be utilized for this type of approach, including adenovirus, adeno-associated virus (AAV) (McLaughlin et al, J. Virol. 62:1963-1973, 1988), Vaccinia virus (Moss et al, Annu. Rev.
  • RNA-DNA hybrid oligonucleotides as described by Cole-Strauss, et al (Science 273:1386-1389, 1996). This technique may allow for site-specific integration of cloned sequences, thereby permitting accurately targeted gene replacement.
  • gene therapies vectors are preferentially targeted to proliferating cells. Methods and viral strains that can be used for such proliferating cell-biased gene therapy are discussed in U.S. Patent No. 6,045,789, which is incorporated herein by reference in its entirety.
  • lipidic and liposome-mediated gene delivery has recently been used successfully for transfection with various genes (for reviews, see Templeton and Lasic, Mol. Biotechnol 11 : 175-180, 1999; Lee and Huang, Crit. Rev. Ther. Drug Carrier Syst. 14:173-206; and Cooper, Semin. Oncol 23:172-187, 1996).
  • cationic liposomes have been analyzed for their ability to transfect monocytic leukemia cells, and shown to be a viable alternative to using viral vectors (de Lima et al, Mol. Membr. Biol. 16:103-109, 1999). Such cationic liposomes can also be targeted to specific cells through the inclusion of, for instance, monoclonal antibodies or other appropriate targeting ligands (Kao et al, Cancer Gene Ther. 3:250-256, 1996).
  • gene therapy can be carried out using antisense or other suppressive constructs, the construction of which is discussed above (Example 8).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, dans certains modes de réalisations, des souches de levure surexprimant un domaine « polo-box » provenant de kinases Cdc5 ou Plk, et présentant par conséquent un schéma de croissance en chaîne à cytokinèse défectueuse. On peut utiliser ces souches, ainsi que les lignées cellulaires équivalentes issues d'autres espèces, pour identifier des composés qui modulent l'activité de la kinase de type polo. Par ailleurs, cette invention concerne des méthodes d'utilisation des peptides relatifs à « polo-box » et des composés qui modulent l'activité kinase de type polo, pour inhiber ou stimuler la prolifération cellulaire. On peut, par exemple, utiliser ces peptides et composés pour traiter une maladie, un trouble ou un état pathologique hyper-proliférant, notamment les tumeurs, via l'inhibition de polo kinase(s).
PCT/US2001/016903 2000-05-23 2001-05-23 Souches de levure permettant d'identifier des inhibiteurs specifiques de polo kinases Ceased WO2001090401A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001263418A AU2001263418A1 (en) 2000-05-23 2001-05-23 Yeast strains to identify specific inhibitors of polo kinases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20658800P 2000-05-23 2000-05-23
US60/206,588 2000-05-23

Publications (2)

Publication Number Publication Date
WO2001090401A2 true WO2001090401A2 (fr) 2001-11-29
WO2001090401A3 WO2001090401A3 (fr) 2002-11-28

Family

ID=22767046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/016903 Ceased WO2001090401A2 (fr) 2000-05-23 2001-05-23 Souches de levure permettant d'identifier des inhibiteurs specifiques de polo kinases

Country Status (2)

Country Link
AU (1) AU2001263418A1 (fr)
WO (1) WO2001090401A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047526A3 (fr) * 2003-11-12 2005-12-08 Cyclacel Ltd Procede
WO2004058161A3 (fr) * 2002-12-20 2005-12-29 Fmc Corp Kinases dites « polo-like » d'hemipteres
EP2258858A1 (fr) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Modèle animal pour le cancer transgénique pour LSD1
WO2011071916A2 (fr) 2009-12-07 2011-06-16 The Johns Hopkins University Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
EP2727996A1 (fr) 2008-11-06 2014-05-07 The Johns-Hopkins University Traitement des inflammations chroniques des voies respiratoires avec des inhibiteurs de NP1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650501A (en) * 1994-06-02 1997-07-22 Mount Sinai Hospital Corporation Serine/threonine kinase and nucleic acids encoding same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058161A3 (fr) * 2002-12-20 2005-12-29 Fmc Corp Kinases dites « polo-like » d'hemipteres
WO2005047526A3 (fr) * 2003-11-12 2005-12-08 Cyclacel Ltd Procede
US7968762B2 (en) 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
EP2727996A1 (fr) 2008-11-06 2014-05-07 The Johns-Hopkins University Traitement des inflammations chroniques des voies respiratoires avec des inhibiteurs de NP1
EP2258858A1 (fr) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Modèle animal pour le cancer transgénique pour LSD1
WO2011071916A2 (fr) 2009-12-07 2011-06-16 The Johns Hopkins University Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement

Also Published As

Publication number Publication date
WO2001090401A3 (fr) 2002-11-28
AU2001263418A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
Lai et al. A human importin-β family protein, transportin-SR2, interacts with the phosphorylated RS domain of SR proteins
Mundt et al. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression
Versele et al. Septin collar formation in budding yeast requires GTP binding and direct phosphorylation by the PAK, Cla4
Hu et al. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells
Ando et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation
Rubnitz et al. ENL, the gene fused with HRX in t (11; 19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells
Nakano et al. The small GTP‐binding protein Rho1 is a multifunctional protein that regulates actin localization, cell polarity, and septum formation in the fission yeast Schizosaccharomyces pombe
CA2119443C (fr) Cycline e humaine
Umen et al. Prp16p, Slu7p, and Prp8p interact with the 3'splice site in two distinct stages during the second catalytic step of pre-mRNA splicing.
CA2148252C (fr) Systeme de piegeage pour l'isolement de nouvelles proteines
US7759476B2 (en) Double-stranded RNAS directed to IKK-2
CA2180570C (fr) Proteine p27 isolee et molecules d'acide nucleique codant cette proteine
EP0898580B1 (fr) Procedes et moyens destines a inhiber l'activite de cdk4
JP2008301815A (ja) 刺激誘導性Ｉ（κ）Ｂキナーゼ［ＩＫＫ］シグナルソーム
US6586577B2 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
WO2001090401A2 (fr) Souches de levure permettant d'identifier des inhibiteurs specifiques de polo kinases
US20030092054A1 (en) Protein complexes and assays for screening anti-cancer agents
Zhou et al. Differential expression, localization and activity of two alternatively spliced isoforms of human APC regulator CDH1
Xu et al. Identification of Rgl3 as a potential binding partner for Rap-family small G-proteins and profilin II
Einarson et al. Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis
US6127158A (en) Ubiquitin conjugating enzymes
US20030039998A1 (en) Method for regulating cell growth and assays related thereto
US6562591B1 (en) Germinal center kinase cell cycle proteins, compositions and methods of use
EP1637540A1 (fr) Des molécules hyperactives de stat et procédés d'essai de l'activation génique
Luo Isolation and functional studies of D. discoideum cyclin B gene during growth and development

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP